BIOVIE INC. (BIVI) - 10-Q Summary
Business Context and Reporting Period
Company: BIOVIE INC.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended December 31, 2025
Business Overview: BioVie is a clinical-stage biopharmaceutical company developing therapies for neurological/neurodegenerative disorders (Alzheimer's, Parkinson's, Long COVID) and advanced liver disease. The company has no product revenue and relies on capital raises and grants to fund operations.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(11,157,032) | $(11,264,561) |
| Net Loss Per Share (Basic/Diluted) | $(1.70) | $(10.54) |
| Cash and Cash Equivalents (Ending) | $20,540,585 | $24,405,517 |
| Working Capital | $18,785,692 | N/A |
| Net Cash Used in Operating Activities | $(7,461,591) | $(12,164,235) |
| Net Cash Provided by Financing Activities | $10,457,629 | $12,725,954 |
| Total Assets | $22,503,293 | N/A |
| Total Liabilities | $3,238,259 | N/A |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $108,000 year-over-year for the six-month period, primarily due to increased interest income and reduced interest expense following the payoff of notes payable in late 2024.
- Operating Expenses: Total operating expenses increased slightly by $132,000. Research and Development (R&D) expenses rose by $511,000 due to the launch of the Long COVID Phase 2 and Parkinson's Phase 2 studies, partially offset by a $379,000 decrease in General and Administrative (G&A) expenses driven by lower stock-based compensation and consultancy fees.
- Capital Raise: In August 2025, the company completed an underwritten public offering raising approximately $10.5 million in net proceeds. This significantly increased cash reserves compared to the prior period.
- Share Count: The weighted average shares outstanding increased significantly (from ~1.1M to ~6.6M for the six-month period) due to the August 2025 offering and a 1:10 reverse stock split effected in July 2025.
- Grant Reimbursements: The company recognized approximately $1.0 million in grant reimbursements from the U.S. Department of Defense for the Long COVID program, reducing net R&D expenses.
Guidance, Outlook, and Risks
- Clinical Pipeline Status:
- Parkinson's Disease: The Phase 2b study (Sunrise) commenced in April 2025 and completed enrollment of 60 patients in December 2025. Topline results are expected in the first half of 2026.
- Long COVID: The Phase 2 ADDRESS-LC study commenced in May 2025. As of December 31, 2025, approximately $6.7 million in costs were incurred with $6.4 million reimbursed.
- Alzheimer's Disease: The Phase 3 trial was underpowered due to protocol violations at 15 sites. While the primary endpoints were not met, descriptive data suggested a slowing of cognitive loss in the per-protocol population. The company is considering adaptive trial features or a new Phase 3 design.
- Liver Disease: Finalizing Phase 3 protocol for BIV201 (terlipressin) targeting a broader ascites population.
- Liquidity and Going Concern: Management states there is "substantial doubt" regarding the company's ability to continue as a going concern without additional financing. Future operations depend on securing equity, loans, or strategic transactions.
- Legal Proceedings: The company is defending a consolidated securities class action lawsuit (denied motion to dismiss in March 2025) and three consolidated shareholder derivative lawsuits (stayed pending the class action resolution). The company believes claims are without merit.
- Spin-off Activity: A subsidiary, Option Therapeutics Inc., was established for the potential spin-off of the Liver Disease Program and filed a Form S-1 for a potential IPO in January 2026.
Investor Verification Checklist
- Cash Runway: Verify the projected burn rate against the $20.5 million cash balance to determine the timeline for the next capital raise.
- Legal Exposure: Monitor the status of the securities class action and derivative lawsuits, as discovery is ongoing and could result in significant costs or settlements.
- Alzheimer's Strategy: Confirm the company's definitive plan for the Alzheimer's program (adaptive trial vs. new Phase 3) given the previous trial's underpowered status.
- Dilution Risk: Review the impact of the 7.9 million outstanding warrants and the recent equity issuance on future shareholder dilution.
- Grant Dependency: Assess the reliability of the $13.1 million DOD grant for the Long COVID program as a funding source.